Final imSAVAR Meeting in Brussels – November 12–13, 2025
On November 12 and 13, the imSAVAR consortium gathered for its final meeting at the Fraunhofer EU Office in Brussels. This event marked the culmination of six years of collaborative research and innovation within the project.
Day 1: Project Recap and Work Package Discussions
The meeting opened with a warm welcome and a comprehensive project recap presented by Kristin Reiche and Hannah Morgan, highlighting key achievements and milestones. Following this, our new EU officer, Oussama Karroum, introduced himself and shared his perspective on the project’s impact.
The remainder of the day was dedicated to detailed presentations of the individual work packages. Partners discussed activities, results, and their alignment with imSAVAR’s overarching objectives. These sessions provided an opportunity to reflect on scientific progress, regulatory insights, and collaborative efforts that shaped the project.
The first day concluded with an enjoyable networking dinner at an authentic Belgian restaurant, fostering informal exchanges and strengthening connections among partners.
Day 2: Final Reporting, Sustainability, and Future Perspectives
The second day began with a presentation by the Project Management Office outlining requirements and activities for the preparation of the final project report. Our EU officer contributed valuable guidance on ensuring a high-quality submission.
Subsequently, Scott Wagers facilitated interactive sessions focused on sustainability and exploitation of imSAVAR’s results. Carmen Sanges introduced ongoing initiatives within the IMI2 project T2EVOLVE, which aims to establish an association to promote innovation, collaboration, and sustainable access to cell-based therapies in Europe. imSAVAR partners are invited to attend this initiative.
After a short break, participants explored strategies to advance key outcomes of imSAVAR—such as the irAOP concept—through new applications in upcoming EU calls. Concrete next steps for these applications were defined, ensuring continuity beyond the project’s official end.
In the final segment, Kirsten Rump provided an update on the current status of data storage and outlined plans for future management of project data.
Closing Remarks
Kristin Reiche and Hannah Morgan concluded the meeting by thanking all partners for their dedication, collaboration, and contributions throughout the past six years. The completion of imSAVAR represents a significant milestone, opening new perspectives for research, regulatory science, and the development of life-saving therapies.